

INPLASY PROTOCOL

To cite: Wei et al. Aspirin Versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis in Patients after Postoperative Joint Surgery: A Meta-Analysis. Inplasy protocol 202320117. doi: 10.37766/inplasy2023.2.0117

Received: 27 February 2023

Published: 27 February 2023

Corresponding author:
Qingqing Wei

13611205836@163.com

Author Affiliation:
Emergency General Hospital.

Support: None.

Review Stage at time of this submission: Preliminary searches.

Conflicts of interest:
None declared.

Aspirin Versus Low-Molecular-Weight Heparin for Venous Thromboembolism Prophylaxis in Patients after Postoperative Joint Surgery: A Meta-Analysis

Wei, QQ¹; Wang, WY²; Miao, GB³; LI, L⁴; Wang, G⁵; Meng, C⁶; Liu P⁷.

Review question / Objective: We sought to conduct a systematic review and meta-analysis to evaluate the safety and efficacy of aspirin versus low molecular weight heparin in the population with postoperative joint surgery.

Condition being studied: All cause death, DVT, PE, wound infection and wound complication.

Information sources: We will search the references in the included trials and personal files. We will request advice from experts in the field. In addition, we will search associated articles from meetings, and contacted the authors of included trials, if need.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 27 February 2023 and was last updated on 27 February 2023 (registration number INPLASY202320117).

INTRODUCTION

Review question / Objective: We sought to conduct a systematic review and meta-analysis to evaluate the safety and efficacy of aspirin versus low molecular weight heparin in the population with postoperative joint surgery.

Condition being studied: All cause death, DVT, PE, wound infection and wound complication.

METHODS

Participant or population: Patients after Postoperative Joint Surgery.

Intervention: Aspirin.

Comparator: Low molecular weight heparin.

Author 5 - Ge Wang.
Author 6 - Chang Meng.
Author 7 - Peng Liu.

Study designs to be included: The search strategy was RCTs.

Eligibility criteria: (1) Patients after Postoperative Joint Surgery. (2) Treat with aspirin or LMWH. (3) Outcomes Indicators: All cause death, DVT, PE, wound infection, wound complication, including one.

Information sources: We will search the references in the included trials and personal files. We will request advice from experts in the field. In addition, we will search associated articles from meetings, and contacted the authors of included trials, if need.

Main outcome(s): DVT, PE, All cause death.

Quality assessment / Risk of bias analysis: We evaluated the methodological quality of the individual studies using the Cochrane risk of bias tool for RCTs.

Strategy of data synthesis: We will consider using the number of events between different groups and the total number of people for analysis, and the results may be expressed in terms of OR or RR.

Subgroup analysis: Aspirin group or aspirin combined mobile compression device(MCD).

Sensitivity analysis: We conducted sensitivity analyses to investigate the influence of a single study on the overall pooled estimate of each predefined outcome.

Country(ies) involved: China.

Keywords: Aspirin; Low-Molecular-Weight Heparin; Venous Thromboembolism; Joint Surgery.

Contributions of each author:

Author 1 - Qingqing Wei.

Author 2 - Weiyang Wang.

Author 3 - Guobin Miao.

Author 4 - Li Li.